Acelity, a global advanced wound care company, today announced that two significant enhancements to the V.A.C.ULTA Therapy System are now available in the U.S. The V.A.C.ULTA Therapy System, Acelity’s latest generation negative pressure wound therapy (NPWT) system, is now enhanced to improve clinicians’ experiences by leveraging first-to-market connectivity technology.

iOn RESULTS Remote Therapy Monitoring (RTM) connects hospitals to Acelity’s unique service and support offering to promote compliance and drive proper patient utilization of therapy. The V.A.C.ULTA 4 Therapy System simplifies functionality, reports summative therapy, and allows for on-screen selection of four different therapies on a single advanced device which can be tailored to a patient’s specific need and clinician’s preference. Designed with outcomes and experience in mind, these enhancements combine Acelity’s expertise in advanced wound care with the latest in technology to provide greater accuracy and certainty for clinicians with the goal of improving outcomes for patients while lowering costs.

“Acelity is leading the transformation to value-based care by enhancing our best-in-class advanced therapies with improvements that take into account the experiences of our customers who are on the front line in treating patients, ” says R. Andrew Eckert, president and chief executive officer of Acelity. “The V.A.C.ULTA™ System has an unmatched reputation in hospitals for delivering the best outcomes for wounds, and with these new features, we can better support doctors and nurses by providing real-time monitoring and data to enhance care delivery.”

(Image credit: Acelity)

iOn RESULTS Remote Therapy Monitoring works in conjunction with the V.A.C.ULTA Therapy System to monitor the therapy units’ performance in the hospital setting. The system enables timely feedback and therapy application optimization to enhance product performance metrics to identify hospital staff training or support needs. 

V.A.C.ULTA 4 Therapy System provides simplified functionality through a software upgrade that provides enhanced pathways to the device’s four negative pressure therapies: V.A.C. Therapy, V.A.C. VERAFLO Therapy, PREVENA Therapy and ABTHERA Therapy. The new system provides a device that allows usage of the four different therapies that can be tailored depending on a patient’s need and the clinician’s varying levels of experience. Therapy setup pathways for each therapy have shown significant reduction in numbers of screens and button pushes, saving clinicians’ time. For example, V.A.C. VERAFLO Therapy can now be initiated with 38 percent fewer steps.

“By simplifying functionality and making their products and therapies more approachable in daily use, Acelity continues to demonstrate an understanding of the burdens we face, which continue to change in an increasingly complex healthcare landscape,” says Elizabeth McElroy, Certified Wound Ostomy Continence Nurse (CWOCN) at Reading Hospital. “These new features are the latest example of how Acelity innovation allows us to focus on our most important job – taking care of people.”

The new V.A.C.ULTA Therapy System enhancements were developed with day-to-day challenges faced by clinicians, administrators and patients in mind. Acelity also recently added FISTULA SOLUTION Devices to help clinicians manage patients with fistula complications. Managing wounds in patients with fistulas is challenging and represented a significant unmet need. These devices provide nurses with a solution to divert fistula effluent away from surrounding tissue, and are used in conjunction with wound management plans ordered by the clinicians.